The DOI matches its Crossref record.
Nonalcoholic Steatohepatitis
Abstract
Nonalcoholic fatty liver disease (NAFLD) is being increasingly recognized as a common liver disorder that represents the hepatic manifestation of the metabolic syndrome, a variably defined aggregate of disorders related to obesity, insulin resistance, type II diabetes, hypertension and hyperlipidemia. Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC) is a documented complication in an as yet unknown percentage of cases of NASH cirrhosis. The diagnosis of nonalcoholic steatohepatitis requires histopathologic evaluation because the lesions of parenchymal injury and fibrosis cannot be detected by imaging studies or laboratory tests. This article will briefly discuss prevalence studies and the pathophysiology of NAFLD and focus on current discussions related to the specific lesions in the pathology of NASH, including the challenges of pediatric NASH and NASH-related cirrhosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Adipose tissue can synthesize and release proinflammatory cytokines and adipokines, including leptin, adiponectin, and resistin; and these factors make up one of the driving mechanisms of IR (Brunt, 2004).”
From Akkermansia muciniphila alleviates high‐fat‐diet ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids (2023) · cites this paper as Brunt, 2004
In the citing paper
“The assessment and severity of NASH is made histologically based on the patterns and degrees of hepatic steatosis, inflammation, and injury, in the absence of significant alcohol consumption.8”
From Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy† (2005) · cites this paper as [8]
Citations
Cited by
Sorted by citations
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationByrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,162
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Prevalence of Fatty Liver in Children and Adolescents
Schwimmer, J. B., Deutsch, R., Kahen, T., Lavine, J. E., Stanley, C. R., & Behling, C. A. (2006) · PEDIATRICS · doi:10.1542/peds.2006-1212 · Cited by 1,477
Prepared, B. (2005) · Heart · doi:10.1136/hrt.2005.079988 · Cited by 1,223
Metadata
- Authors
- Brunt, E. M.
- Affiliations
- Saint Louis University Hospital (US)
- Corresponding author
- Elizabeth M. Brunt
- ORCID
- Elizabeth M. Brunt
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2004-01
- Volume
- 24
- Issue
- 1
- Pages
- 3-20
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W3149847267
- Cited by
- 481
- References
- 0
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 9 · 2023: 8 · 2022: 4 · 2021: 6 · 2020: 13 · 2019: 4 · 2018: 18 · 2017: 14 · 2016: 24 · 2015: 25 · 2014: 26 · 2013: 22 · 2012: 31
- FWCI
- 29.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Seminars in Liver Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, metabolic syndrome, liver fibrosis, liver cirrhosis, hepatocellular carcinoma, histopathology, pathophysiology, prevalence, insulin resistance, obesity
- MeSH terms
- Adolescent, Adult, Child, Fatty Liver, Fatty Liver, Alcoholic, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Liver Neoplasms, Prevalence, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
